Acute Coronary Syndrome - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 109
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AD108C1B498EN
Leaflet:

Download PDF Leaflet

Acute Coronary Syndrome - Pipeline Review, H2 2016
Acute Coronary Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Coronary Syndrome – Pipeline Review, H2 2016, provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape.

Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Coronary Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.

Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acute Coronary Syndrome Overview
Therapeutics Development
Pipeline Products for Acute Coronary Syndrome - Overview
Acute Coronary Syndrome - Therapeutics under Development by Companies
Acute Coronary Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Coronary Syndrome - Products under Development by Companies
Acute Coronary Syndrome - Companies Involved in Therapeutics Development
advanceCor GmbH
Arena Pharmaceuticals, Inc.
Ascendia Pharmaceuticals LLC
Athera Biotechnologies AB
Bayer AG
Cardiome Pharma Corp.
Cerenis Therapeutics Holding SA
CSL Limited
Esperion Therapeutics, Inc.
HitGen LTD
Japan Tobacco Inc.
Lee's Pharmaceutical Holdings Limited
LipimetiX Development Inc
MedImmune LLC
Pfizer Inc.
The Medicines Company
Verseon Corporation
Acute Coronary Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
4-WF - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
AEM-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEM-2802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Acute Coronary Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clopidogrel bisulphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COR-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalcetrapib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDCO-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-6012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PC-mAb - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06282999 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temanogrel hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirofiban hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Coronary Syndrome - Dormant Projects
Acute Coronary Syndrome - Discontinued Products
Acute Coronary Syndrome - Product Development Milestones
Featured News & Press Releases
Sep 01, 2016: FDA Approves New AGGRASTAT Product Format
Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication
May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy
Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015
Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients
Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Coronary Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2016
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Acute Coronary Syndrome - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2016
Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2016
Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2016
Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2016
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2016
Acute Coronary Syndrome - Pipeline by HitGen LTD, H2 2016
Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H2 2016
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Acute Coronary Syndrome - Pipeline by LipimetiX Development Inc, H2 2016
Acute Coronary Syndrome - Pipeline by MedImmune LLC, H2 2016
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2016
Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2016
Acute Coronary Syndrome - Pipeline by Verseon Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Coronary Syndrome - Dormant Projects, H2 2016
Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2016
Acute Coronary Syndrome - Discontinued Products, H2 2016
Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Coronary Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Acute Coronary Syndrome: Market Research Report US$ 3,450.00 Apr, 2010 · 752 pages

Ask Your Question

Acute Coronary Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: